Payment overview · 2025
General Payments
$159.29
9 reported records · 4 companies
Healthcare provider profile · identity verified
Matthew Warren Hurley, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ROLLA, MO · NPI 1821362088
Verified facts
What the public records show
CMS Open Payments records show Matthew Warren Hurley, M.D. received $159.29 in general payments during 2025 across 9 reported records.
PFIZER INC. accounted for 52.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $83.44 | 52.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.10 | 23.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.65 | 14.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.10 | 9.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $159.29 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $59.44 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $59.44 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 18 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
116 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 720 | 97 |
| Lisinopril | Lisinopril | 607 | 137 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 570 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 518 | 107 |
| Omeprazole | Omeprazole | 424 | 92 |
| Atorvastatin Calcium | Atorvastatin Calcium | 413 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 347 | 81 |
| Gabapentin | Gabapentin | 328 | 62 |
| Metformin Hcl | Metformin Hcl | 285 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 228 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 221 | 44 |
| Montelukast Sodium | Montelukast Sodium | 220 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 212 | 34 |
| Losartan Potassium | Losartan Potassium | 210 | 55 |
| Pregabalin | Pregabalin | 207 | 33 |
| Trazodone Hcl | Trazodone Hcl | 206 | 42 |
| Alprazolam | Alprazolam | 200 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 195 | 41 |
| Oxycodone Hcl | Oxycodone Hcl | 183 | 23 |
| Buspirone Hcl | Buspirone Hcl | 176 | 26 |
| Meloxicam | Meloxicam | 173 | 41 |
| Potassium Chloride | Potassium Chloride | 173 | 33 |
| Tramadol Hcl | Tramadol Hcl | 173 | 54 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 167 | 50 |
| Famotidine | Famotidine | 166 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 160 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 160 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 152 | 47 |
| Furosemide | Furosemide | 142 | 31 |
| Glipizide | Glipizide | 135 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 135 | 34 |
| Carvedilol | Carvedilol | 131 | 30 |
| Celecoxib | Celecoxib | 131 | 31 |
| Jardiance | Empagliflozin | 125 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 124 | 23 |
| Methylprednisolone | Methylprednisolone | 119 | 91 |
| Morphine Sulfate Er | Morphine Sulfate | 118 | 13 |
| Simvastatin | Simvastatin | 118 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 20 |
| Eliquis | Apixaban | 116 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 29 |
| Allopurinol | Allopurinol | 109 | 22 |
| Mounjaro | Tirzepatide | 109 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 100 | 20 |
| Sertraline Hcl | Sertraline Hcl | 94 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 25 |
| Azithromycin | Azithromycin | 88 | 63 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 85 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 85 | 17 |
| Mirtazapine | Mirtazapine | 83 | 15 |
| Trulicity | Dulaglutide | 82 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 15 |
| Ondansetron Odt | Ondansetron | 78 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 77 | 13 |
| Lorazepam | Lorazepam | 76 | 17 |
| Ezetimibe | Ezetimibe | 75 | 17 |
| Baclofen | Baclofen | 73 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 71 | 23 |
| Bupropion Xl | Bupropion Hcl | 70 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 18 |
| Metformin Hcl Er | Metformin Hcl | 68 | 22 |
| Temazepam | Temazepam | 67 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | 17 |
| Januvia | Sitagliptin Phosphate | 65 | suppressed |
| Clonazepam | Clonazepam | 64 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 63 | suppressed |
| Vascepa | Icosapent Ethyl | 63 | suppressed |
| Aripiprazole | Aripiprazole | 61 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 13 |
| Xarelto | Rivaroxaban | 59 | 12 |
| Lamotrigine | Lamotrigine | 56 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 56 | suppressed |
| Ozempic | Semaglutide | 56 | 14 |
| Glimepiride | Glimepiride | 50 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 49 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 11 |
| Chlorthalidone | Chlorthalidone | 45 | 11 |
| Glipizide Er | Glipizide | 44 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 11 |
| Morphine Sulfate | Morphine Sulfate | 44 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 43 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | suppressed |
| Synthroid | Levothyroxine Sodium | 42 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | suppressed |
| Spironolactone | Spironolactone | 40 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 36 |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 39 | 11 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 11 |
| Cephalexin | Cephalexin | 34 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Nystatin | Nystatin | 34 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Ibuprofen | Ibuprofen | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 22 |
| Prednisone | Prednisone | 32 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Oxycontin | Oxycodone Hcl | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 27 | 27 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 26 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 24 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 20 |
| Estradiol | Estradiol | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Movantik | Naloxegol Oxalate | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Belsomra | Suvorexant | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Xifaxan | Rifaximin | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 11 |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Armodafinil | Armodafinil | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 13 | suppressed |
| Isradipine | Isradipine | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Xanax | Alprazolam | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Caplyta | Lumateperone Tosylate | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Mesalamine Dr | Mesalamine | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $159.29 · 9 records | PFIZER INC. | ABRYSVO, AREXVY, BEXSERO, COMIRNATY, Dexcom G6 Transmitter, NURTEC ODT, PREVNAR 20, QULIPTA, SHINGRIX, UBRELVY, VRAYLAR, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error